CVI Pharmaceuticals Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $4.63M

  • Investors
  • 3

CVI Pharmaceuticals General Information

Description

Developer of small-molecule oral therapies intended to aid in the treatment of cardiovascular and metabolic diseases such as hypercholesterolemia, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), obesity, and other rare metabolic diseases. The company's main product chemistry class 1 oral small-molecule lipid-lowering drug CVI-LM001 has been tested in vivo and in vitro, enabling patients to get treatment without any side effects.

Contact Information

Website
cvipharma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 898 Ha Lei Road, Building 1, Suite 304, Zhang
  • Jiang High Tech Park, Pudong New District
  • Shanghai, 201203
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Corporate Office
  • 898 Ha Lei Road, Building 1, Suite 304, Zhang
  • Jiang High Tech Park, Pudong New District
  • Shanghai, 201203
  • China
+86 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CVI Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 21-Jul-2021 $4.63M Completed Clinical Trials - Phase 2
4. Secondary Transaction - Private 26-Feb-2020 Completed Clinical Trials - Phase 1
3. Later Stage VC 16-Jun-2016 Completed Pre-Clinical Trials
2. Later Stage VC 25-Nov-2013 Completed Pre-Clinical Trials
1. Seed Round 31-Dec-2007 Completed Startup
To view CVI Pharmaceuticals’s complete valuation and funding history, request access »

CVI Pharmaceuticals Patents

CVI Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022048620-A1 Polymorphs of crystalline forms of 3, 10-dimethoxy-5, 8, 13, 13a-tetrahydro-6h-isoquinolino [3, 2-a] isoquinolin-9-yl 3-fluorobenzenesulfonate and salts thereof Inactive 03-Sep-2020
US-20230279002-A1 Polymorphs of crystalline forms of 3,10-dimethoxy-5,8,13,13a-tetrahydro-6h-isoquinolino[3,2-a]isoquinolin-9-yl 3-fluorobenzenesulfonate and salts thereof Inactive 03-Sep-2020
US-20220387403-A1 Compounds, compositions and methods for treating nash, nafld, and obesity Inactive 01-Oct-2019
WO-2021067490-A1 Compounds, compositions and methods for treating nash, nafld, and obesity Inactive 01-Oct-2019
US-20110009628-A1 Compounds and compositions for modulating lipid levels and methods of preparing same Inactive 08-Jul-2009 C07D471/04
To view CVI Pharmaceuticals’s complete patent history, request access »

CVI Pharmaceuticals Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Wuhan Haite Biopharmaceutical Corporation Minority
BVCF Venture Capital Minority
5Y Capital Venture Capital Minority
To view CVI Pharmaceuticals’s complete investors history, request access »

CVI Pharmaceuticals FAQs

  • When was CVI Pharmaceuticals founded?

    CVI Pharmaceuticals was founded in 2007.

  • Where is CVI Pharmaceuticals headquartered?

    CVI Pharmaceuticals is headquartered in Shanghai, China.

  • What industry is CVI Pharmaceuticals in?

    CVI Pharmaceuticals’s primary industry is Drug Discovery.

  • Is CVI Pharmaceuticals a private or public company?

    CVI Pharmaceuticals is a Private company.

  • What is the current valuation of CVI Pharmaceuticals?

    The current valuation of CVI Pharmaceuticals is .

  • What is CVI Pharmaceuticals’s current revenue?

    The current revenue for CVI Pharmaceuticals is .

  • How much funding has CVI Pharmaceuticals raised over time?

    CVI Pharmaceuticals has raised $4.63M.

  • Who are CVI Pharmaceuticals’s investors?

    Wuhan Haite Biopharmaceutical, BVCF, and 5Y Capital have invested in CVI Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process